Search results
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People...
Benzinga· 5 days ago– Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p < 0.001) – – At week 24, 100% of CT-388
Best Ads of the Week: Coi Leray kicks it with Foot Locker & Dove decodes mom life with AI
The Drum· 6 days agoThis week, Editora Taverna fought the good fight against gay conversion therapy Brazil, Vivo rallied...
Genprex dosing subjects in trial of combination therapy for small-cell lung cancer
Clinical Trials Arena via Yahoo Finance· 6 days agoThe Acclaim-3 trial aims to determine the safety and optimal dosage of Reqorsa (quaratusugene...
Mirikizumab Shows Promise for Moderate to Severe Crohn's
Medscape· 21 hours agoAlready approved for ulcerative colitis, the monoclonal antibody mirikizumab met study endpoints for...
No Improvement in OS With Atezolizumab in Relapsing TNBC
Medscape· 21 hours agoEarly relapsing disease has again shown the limitations of immunotherapy in triple-negative breast...
Biotech company lays off over a hundred Bay Area workers
San Francisco Chronicle· 4 days agoBioMarin Pharmaceutical, a San Rafael-based biotech company specializing in drugs for genetic...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 7 days agoOSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced its unaudited financial results
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with...
Morningstar· 13 hours agoPRINCETON, NJ / ACCESSWIRE / May 20, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs ...
Spyre Therapeutics names Sandra Milligan to board By Investing.com
Investing.com· 5 days agoSpyre Therapeutics, Inc. (NASDAQ: SYRE), a biotechnology company focusing on the development of...
Perioperative Nivolumab Boosts EFS in Resectable Lung Cancer
MedPage Today· 6 days agoCheckMate 77T trial shows 42% reduction in risk of tumor recurrence, progression, or death